If you would like to learn about Breo, the once daily asthma medication,1 please click here:
Breo ElliptaIf you would like to learn about Breo, the once daily asthma medication,1 please click here:
Breo ElliptaFor further product information on Seretide, view the Consumer Medicine Information (CMI) and Data Sheet at www.medsafe.govt.nz.
Consumer Information | Your Privacy | Terms & Conditions | Accessibility | Contact Us
References: 1. Breo Ellipta Data sheet, NZ
Seretide® (fluticasone propionate/salmeterol xinafoate; available as a 50/25, 125/25 or 250/25mcg per actuation inhaler, or as a 100/50 or 250/50mcg per actuation Accuhaler®) is a Prescription Medicine. Seretide is for the regular treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). Seretide is a fully funded medicine. Seretide 250/25mcg inhaler is a private purchase medicine. Use strictly as directed. Seretide is not for relief of acute symptoms. Always carry your reliever inhaler. Do not discontinue Seretide abruptly. This medicine has risks and benefits. Tell your doctor: If you are taking any other medicines or herbal remedies, you have pulmonary tuberculosis (TB), a thyroid problem or a heart problem, or you are having treatment for high blood pressure. Side Effects: Headache, soreness in the mouth, throat or tongue, hoarseness, muscle cramps, pains in joints, ‘shaky’ feeling or fast heart rate. Lung infection (pneumonia) has been reported commonly in patients with COPD. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. For more information see Seretide Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor's charges apply. Ask your doctor if Seretide is right for you. Seretide and Accuhaler are registered trade marks of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland. Breo® Ellipta® (fluticasone furoate/vilanterol trifenatate inhaler 100/25mcg per inhalation) is a Prescription Medicine. Breo Ellipta is used for the regular treatment of asthma (12 years of age and older) and for adults with Chronic Obstructive Pulmonary Disease (COPD). Breo Ellipta 100/25mcg is a fully funded medicine; Breo Ellipta 200/25mcg is a private purchase medicine (dose indicated in asthma only). Use strictly as directed. Breo Ellipta is not for relief of acute symptoms; a separate reliever inhaler may be required. Always carry your reliever inhaler. Do not discontinue Breo Ellipta abruptly. This medicine has risks and benefits. Tell your doctor: If you are taking any other medicines or herbal remedies, you have liver disease, heart problems, high blood pressure, pulmonary tuberculosis (TB), infection of the lungs (pneumonia) or weak bones (oesteoporosis). Side Effects: Headache, common cold, oral thrush, infection of the nose sinuses or throat, flu (influenza), pain and irritation at the back of the mouth and throat, inflammation of the sinuses, pneumonia (in patients with COPD) and weakening of the bones, leading to fractures. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. For more information see Breo Ellipta Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor's charges apply. Ask your doctor if Breo Ellipta is right for you. Breo and Ellipta are registered trade marks of the GlaxoSmithKline group of companies. Breo Ellipta was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland.
Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NA10510/18OC/FPS/180001
Copyright By GlaxoSmithKline